Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Multiple myeloma (MM) remains incurable due to relapse and chemotherapy resistance.
• Novel therapeutic strategies are crucial for effective MM treatment.
• Anlotinib, a multi-targeted tyrosine kinase inhibitor (TKI), has shown antitumor potential but its efficacy in MM was unknown.

Purpose of the Study:

• To investigate the anti-MM effects of anlotinib.
• To explore the underlying molecular mechanisms of anlotinib in MM.
• To evaluate anlotinib's efficacy against bortezomib-resistant MM cells.

Main Methods:

• In vitro cytotoxicity assays on MM cell lines.
• In vivo studies using a mouse xenograft model of MM.
• Analysis of cell cycle, apoptosis, and key signaling pathways.
• Identification of direct molecular targets of anlotinib.

Main Results:

• Anlotinib demonstrated significant cytotoxicity against MM cells, even in the bone marrow microenvironment.
• Anlotinib suppressed tumor growth in a mouse xenograft model.
• Anlotinib induced cell cycle arrest and apoptosis, with c-Myc identified as a direct target.
• Anlotinib showed efficacy against bortezomib-resistant MM cells.

Conclusions:

• Anlotinib exhibits potent anti-MM activity in vitro and in vivo.
• Anlotinib's mechanism involves c-Myc degradation, leading to apoptosis.
• Anlotinib is a promising candidate for clinical application in treating multiple myeloma, including resistant cases.